Prognosis and endocrine therapy selection for patients with low hormone receptor-positive breast cancer following neoadjuvant chemotherapy: A retrospective study of 570 patients in China.

Prognosis and endocrine therapy selection for patients with low hormone receptor-positive breast cancer following neoadjuvant chemotherapy: A retrospective study of 570 patients in China. Oncol Lett. 2019 Dec;18(6):6690-6696 Authors: Ding Y, Ding K, Yu K, Zou D, Yang H, He X, Mo W, Yu X, Ding X Abstract The 2010 American Society of Clinical Oncology guidelines have reduced the immunohistochemistry cut-off value for determining estrogen receptor b positivity from 10 to 1% of stained cells in breast cancer. In clinical practice, low-hormone receptor positive (low HR+) tumors are classified in the luminal subtype, although they exhibit aggressive features and poor prognosis. Information regarding the prognosis of patients with breast cancer following treatment with optimal endocrine therapy and neoadjuvant chemotherapy (NAC) is currently lacking. In the present study, the differences in clinical characteristics and survival of patients with breast cancer were compared among those with low and high HR+ breast cancer who received NAC. Furthermore, the effects of different types of endocrine therapies on the prognosis of patients with breast cancer were compared. The study population comprised patients with primary breast cancer who were treated at the Zhejiang Cancer Hospital between January, 2007 and December, 2017. Patients were divided into three groups based on the results of immunohistochemistry: HR+ (positive staining>10%), HR- (positive staining
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research

Related Links:

Authors: Heitz F, Kümmel S, Lederer B, Solbach C, Engels K, Ataseven B, Sinn B, Blohmer JU, Denkert C, Barinoff J, Fisseler-Eckhoff A, Loibl S Abstract Introduction Oestrogen receptor beta (ER-β) is abundantly expressed in breast cancer (BC), but its impact on neoadjuvant chemotherapy outcome is unknown. Patients and Methods Patients treated in the neoadjuvant GeparTrio trial with available tissue for immunohistochemical analyses were included. Nuclear ER-β expression was correlated with clinico-pathologic characteristics. The impact of its expression on pathological complete response (pCR [ypT0/ypN0...
Source: Geburtshilfe und Frauenheilkunde - Category: OBGYN Tags: Geburtshilfe Frauenheilkd Source Type: research
CONCLUSIONS: LPBC was marginally associated with higher pCR rate than non-LPBC in LT treated HER2+ BC patients. Quantitative assessment of the immune infiltrate by m-IF is feasible and may help correlate individual immune cell subpopulations and immune cell profiles with treatment response. PMID: 31653641 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
ConclusionsWomen who received NET had similar rates of BCS compared to women who received NAC. Those who received NET for longer treatment durations had increased odds of BCS and downstaging compared to women who did not receive neoadjuvant therapy.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
AbstractBackgroundHER2 blockade in combination with chemotherapy (CT) remains the treatment of choice for patients with early HER2+ BC, irrespective of ER status. Patients with HER2+ early BC co-expressing ER may benefit from HER2 blockade in combination with endocrine therapy (ET) and new targeted agents. Elderly patients benefit from HER2 blockade as much as younger ones but they have higher risks of adverse events, mostly induced by the CT partner, making de-escalation of CT appealing. Recent data have elucidated cyclin-dependent kinases 4 and 6 (CDK4/6) as key therapeutic targets functioning downstream of both ER and H...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Authors: Giridhar KV, Liu MC Abstract Introduction: Biomarker assessment is fundamental to managing patients with invasive breast cancer. While the assessment of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 is mandatory for all invasive breast tumors, recent advances in our understanding of tumor biology have uncovered a growing list of clinically relevant biomarkers. Areas covered: In early stage breast cancer, we focus on dynamic changes in Ki-67 during neoadjuvant endocrine therapy and multigene prognostic assays to guide adjuvant chemotherapy decisions. In advanced brea...
Source: Expert Review of Molecular Diagnostics - Category: Laboratory Medicine Tags: Expert Rev Mol Diagn Source Type: research
AbstractBackgroundNeoadjuvant chemotherapy (NACT) is often recommended for patients with node-positive invasive lobular carcinoma (ILC) despite unclear benefit in this largely hormone receptor-positive (HR+) group. We sought to compare overall survival (OS) between patients with node-positive ILC who received neoadjuvant endocrine therapy (NET) and those who received NACT.MethodsWomen with cT1 –4c, cN1–3 HR+ ILC in the National Cancer Data Base (2004–2014) who underwent surgery following neoadjuvant therapy were identified. Kaplan–Meier curves and Cox proportional hazards modeling were used t...
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
Tomás Pascual1,2, Miguel Martin3,4,5, Aranzazu Fernández-Martínez6, Laia Paré1,2, Emilio Alba4,5,7, Álvaro Rodríguez-Lescure4,8, Giuseppe Perrone9, Javier Cortés10,11, Serafín Morales12, Ana Lluch4,5,13,14,15, Ander Urruticoechea16, Blanca González-Farré2,17, Patricia Galván1, Pedro Jares17, Adela Rodriguez1, Nuria Chic1, Daniela Righi9, Juan Miguel Cejalvo1, Giuseppe Tonini9, Barbara Adamo1, Maria Vidal1, Patricia Villagrasa2, Montserrat Muñoz1 and Aleix Prat1,2* 1Medical Oncology Department, Hospital Clinic de Barcelona, Barcelona,...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusion: The administration of trastuzumab should be considered standard treatment for HER2-positive patients who have achieved pCR after NACT alone.Breast Care
Source: Breast Care - Category: Cancer & Oncology Source Type: research
Condition:   Breast Cancer Interventions:   Biological: Pembrolizumab (K);   Drug: Placebo (P);   Drug: Paclitaxel (X);   Drug: Doxorubicin hydrochloride (A);   Drug: Epirubicin (E);   Drug: Cyclophosphamide (C);   Drug: Endocrine therapy;   Radiation: Radiation therapy;   Procedure: Surgery Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting
Source: - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | China Health | Endocrine Therapy | Hormones | Hospitals | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Study | Tamoxifen